Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27660641 | 0.98 | HSP90AB1 (0.42) | HSP90AB1ALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL31176839 | 0.82 | RPS6KB2 (0.42) | ALDH1A1LMNATP53L3MBTL1CES2 | |
| SCHEMBL7958215 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL8139675 | 0.81 | HSP90AB1 (0.52) | HSP90AB1ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL1551334 | 0.81 | HSP90AB1 (0.43) | HSP90AB1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27351557 | 0.80 | HSP90AB1 (0.50) | HSP90AB1ALDH1A1SMN1; SMN2NPC1TP53 | |
| SCHEMBL27660644 | 0.80 | HSP90AB1 (0.42) | HSP90AB1ALDH1A1SMN1; SMN2NPC1TP53 | |
| SCHEMBL8239568 | 0.80 | ALDH1A1 (0.38) | ALDH1A1LMNASMN1; SMN2CES2CES1 | |
| SCHEMBL13185510 | 0.79 | GSK3B (0.44) | HSP90AB1ALDH1A1LMNANPC1TP53 | |
| SCHEMBL2332640 | 0.79 | PARP1 (0.45) | HSP90AB1ALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2021129817-A1 | PYRIMIDINE-BASED COMPOUND HAVING INHIBITORY EFFECT OF KETOHEXOKINASE (KHK) | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2533638-B1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9187447-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759548-B2 | S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| CN-102869255-A | Novel S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-01-09 | — | — | CN | disclosed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| CN-1956971-A | Novel fused heterocycles and application thereof | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | HSP90AB1 1328/4885ALDH1A1 344/4885LMNA 4728/4885 |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | HSP90AB1 1328/4885ALDH1A1 344/4885LMNA 4728/4885 |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | HSP90AB1 1328/4885ALDH1A1 344/4885LMNA 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.